Astrazeneca-Sputnik jabs in combo show a better immune response: RDIF
Preliminary results from Azerbaijan trials have been announced20-08-2021
20-08-2021
AstraZeneca boss tops CEO pay chart in UK: Survey
With many businesses plunging into sharp losses as the world suffered lockdowns, CEOs of London's biggest listed companies saw median annual pay drop 17 percent, the High Pay Centre think tank said.19-08-2021
RDIF proposes Pfizer conduct joint trial with Sputnik Light as booster shot
The Russian Direct Investment Fund (RDIF) has proposed that US drugmaker Pfizer start joint trials with Sputnik Light as a booster COVID-19 vaccine shot, the RDIF said on Wednesday."Delta cases surge in US & Israel shows mRNA vaccines need a heterogeneous booster to strengthen & prolong immune response. #SputnikV pioneered mix & match approach, combo trials & showed 83.1% efficacy vs Delta. Today RDIF offers Pfizer to start trial with Sputnik Light as booster," it said in a Tweet.It further said that Sputnik V is the first in the world to offer combo trial to AstraZeneca in November 2020, co-sponsored mix & match trials with AstraZeneca, Moderna and Sinopharm."Sputnik V was the 1st in the world to offer combo trial to AstraZeneca in Nov 2020, co-sponsored mix & match trials with AstraZeneca, Moderna & Sinopharm. Since then heterogeneous boosting pioneered by Sputnik proved to be effective vs mutations," it added further.According to an official...11-08-2021
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
AstraZeneca Pharma India Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here10-08-2021
AstraZeneca Pharma India Ltd - 506820 - Appointment Of Ms. Revathy Ashok As Independent Director For A Second Term Of 5 Years
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform that at the Company's 42nd Annual General Meeting held on August 9, 2021, the members have approved the re-appointment of Ms. Revathy Ashok, as an Independent Director (DIN: 00057539) for a second term of 5 years i.e., with effect from December 2, 2021 till December 1, 2026. A brief profile of Ms. Revathy Ashok is enclosed. Further, in compliance with circular no. LIST/COMP/14/2018-19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE respectively, we affirm that Ms. Revathy Ashok is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. Ms. Revathy Ashok is not related to any other director of AstraZeneca Pharma India Limited.10-08-2021
AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform that at the Company's 42nd Annual General Meeting held on August 9, 2021, the members have approved the re-appointment of M/s Price Waterhouse & Co, Chartered Accountants LLP (Firm Registration No 304026E/E-300009) as Statutory Auditors of the Company for a second term of 5 years i.e., to hold office till the conclusion of the 47th Annual General Meeting of the Company.10-08-2021
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Pursuant to Clause 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the details regarding voting results of 42nd Annual General Meeting of the Company held on Monday, August 9, 2021 at 3.00 pm through Video Conferencing/ Other Audio Visual Means along with the scrutinizer's report.10-08-2021
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Fixes Record Date for Interim Dividend
AstraZeneca Pharma India Ltd has informed BSE that the Company has fixed August 20, 2021 as the Record Date for the purpose of Payment of Interim Dividend.10-08-2021
AstraZeneca Pharma India Ltd - 506820 - Summary Of Proceedings Of 42Nd Annual General Meeting
Pursuant to the provisions of Regulation 30 read with Part A of Schedule III to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the following business were transacted at the 42nd Annual General Meeting (AGM) of the Company held on August 9, 2021 at 3.00 P.M. through Video Conferencing/Other Audio Visual Means. Kindly note that voting results will be announced upon the receipt of Scrutinizer's Report and will be submitted as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.09-08-2021